Skip to main content

Alnylam and Merck Scuttle $120M-Plus RNAi Drug-Development Partnership

NEW YORK (GenomeWeb News) — Alnylam and Merck today said they have ended an ongoing RNAi drug-development alliance, and Alnylam has rescinded its IP grants related to any Merck development programs.
The deal was worth more than $120 million to Alnylam and ended on a mutually agreed upon note. The companies did not elaborate.
"It is fundamentally in our best interests to terminate our Merck collaboration," said Alnylam CEO John Maraganore. "We wish our colleagues at Merck the best of luck in their efforts.”
The scuttled agreement comprised two deals the firms consolidated in July 2006, and that focused on nine therapeutic targets. The amended deal also offered Alnylam accelerated funding.
The 2006 agreement offered Alnylam more than $120 million in milestones and royalties from products developed and commercialized from the programs, and gave Alnylam the opportunity to co-promote RNAi therapeutic products in the US.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.